Born: 1963. Title: Chief Scientific Officer.
Education: Doctor of Philosophy (D. Phil.) in chemistry from Oxford University.
Background: Former head of Biological Sciences at Boehringer Ingelheim (Canada) Ltd., Head of Therapeutic Research at Shire and various positions at Pfizer and GlaxoSmithKline in the field of development and research.
Shares in Medivir: 8,887 class B shares.
Born: 1969. Title: Chief Financial Officer.
Education: B.Sc. in Finance and Business Administration.
Background: Former CFO at OneMed AB and Aditro Holding AB, SVP Finance and M&A at Thule Group AB and Cell Network, Cash Manager at SCA Finans, and auditor at Ernst & Young.
Shares in Medivir: 8,000 class B shares.
Born: 1975 Title: Chief Information Officer.
Education: PhD from Coventry University, BSc in Systems Science from Linkoping University
Background: Former Technical Director for G4S Risk Management, India Country Manager for Hill & Associates, e-Governance advisor for Iraqi authorities, CIO for the UN OPS Kosovo mission, as well as a series of positions with the UN and international organisations in roles relating to IT, security, decision support systems, innovation, and digitalisation.
Shares in Medivir: 0
Born: 1965. Title: Executive Vice President Strategic Regulatory Affairs.
Education: M. Sc. in Pharmacy, trained at Uppsala University.
Background: Former Head of Regulatory Affairs at Orexo AB. Extensive experience from a number of large pharmaceutical companies, including 12 years as Senior Global Regulatory Affairs Director at AstraZeneca, and, in particular, international, strategic duties within Regulatory Affairs. Åsa has also worked for AstraZeneca in Canada and Japan.
Shares in Medivir: 0.
Born: 1974. Title: President and CEO.
Education: B. Sc. Finance and Information Systems from New York University and Masters in Business Administration from Columbia Business School.
Employed: Joined Medivir in 2015 as EVP, Strategic Business Development.
Background: Previously Vice President, Business Development at LifeCell Corporation and 12 years of investment banking experience in biotech and pharma advisory and capital raising at Merrill Lynch & Co. and Gerard Klauer Mattison & Co.
Shares in Medivir: 5,353 class B shares.